VerImmune
Latest round
- Series A
Last raised
- Aug 2024
Total raised
- $9M
Investors
- 7
About VerImmune
Founded in 2019 by Joshua Wang (CEO) and based in Washington, US, VerImmune, Inc. operates as a developer of a biotechnology therapy that helps redirect the body’s pre-existing immunity to kill cancer cells. In November 2025, VerImmune Inc. The firm employs a proprietary technology engine called ViP (Virus-inspired Particle) based on the natural virology of papillomaviruses that improved targeting and helps in the development of various platform delivery medicine. The firm’s breakthrough solution is an anti-tumor immune redirection that treats cancer by harnessing the body's immune memory against pathogens and childhood vaccines.
Who invested in VerImmune
7 investors across 3 rounds
See all investors in VerImmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VerImmune
Who invested in VerImmune?
VerImmune has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VerImmune raised?
VerImmune has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did VerImmune last raise money?
VerImmune's most recent round on record is a Series A, in Aug 2024.
What does VerImmune do?
Founded in 2019 by Joshua Wang (CEO) and based in Washington, US, VerImmune, Inc.
Where is VerImmune headquartered?
VerImmune is headquartered in Washington, US.
Which VCs invest in companies like VerImmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at VerImmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like VerImmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.